GlassScriptPhysician profile
Mallik Kalepu
NPI 1083749303
$6,054.42
in general payments reported to CMS, 2019-2025
26 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,616 · 2020: $526 · 2021: $876 · 2022: $817 · 2023: $824 · 2024: $673 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,677.35 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,439.27 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $332.19 | 2020-2025 | |
| Lilly USA, LLC | $308.43 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $294.66 | 2019-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $257.04 | 2019-2024 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $250.00 | 2025 | Breztri |
| Insmed, INC. | $246.06 | 2019-2021 | |
| Boston Scientific Corporation | $244.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $172.33 | 2019-2022 | |
| Amgen INC. | $132.95 | 2022 | |
| Mallinckrodt Enterprises LLC | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.86 | 2025 | |
| Exact Sciences Corporation | $98.88 | 2023-2024 | Cologuard Collection Kit |
| Intuitive Surgical, INC. | $75.96 | 2023 | Da Vinci Surgical System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59.73 | 2019-2022 | |
| Mannkind Corporation | $29.88 | 2024 | |
| Dexcom, INC. | $29.36 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $24.85 | 2019 | |
| Sanofi Pasteur INC. | $24.00 | 2019 | |
| Shield Therapeutics INC | $22.60 | 2024 | |
| Avanir Pharmaceuticals, INC. | $21.55 | 2019 | |
| Global Blood Therapeutics, INC. | $21.40 | 2020 | |
| Phadia US INC. | $20.36 | 2024 | Immunocap |
| Lupin INC. | $17.42 | 2019 | |
| Gilead Sciences, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallik Kalepu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.